RAPT Therapeutics, Inc. (RAPT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
RAPT currently has 27M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 341.4% over the past 2 years, indicating aggressive capital raising. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 06, 2025 |
10-Q filing | 27.0M shares outstanding |
27M | 0 |
| Jun 16, 2025 |
Stock Split
8-K filing: Stock split 1-for-8 | Outstanding: 132,288,686 → 16,500,000 |
17M | 9.7M |
| May 08, 2025 |
10-Q filing | 132.3M shares outstanding |
130M | 77M |
| Mar 06, 2025 |
10-K filing | 132.0M shares outstanding |
130M | 77M |
| Jan 21, 2025 |
S-3 filing: This prospectus relates to the offer and resale by the selling stockholders of up to an aggregate of 176,452,000 shares of our common stock, issued by us in a private placement on December 27, 2024. |
35M | 170M |
| Dec 23, 2024 |
8-K filing: RAPT Therapeutics, Inc. entered into a Securities Purchase Agreement to issue and sell 100,000,000 shares of common stock at $0.85 per share and pre-funded warrants to purchase up to 76,452,000 shares of common stock at $0.8499 per warrant, for gross proceeds of approximately $150 million. ($149.98M proceeds) |
35M | 0 |
| Nov 12, 2024 |
10-Q filing | 35.0M shares outstanding |
35M | 0 |
| Aug 08, 2024 |
10-Q filing | 34.9M shares outstanding |
35M | 0 |
| May 09, 2024 |
10-Q filing | 34.9M shares outstanding |
35M | 0 |
| Mar 07, 2024 |
10-K filing | 34.8M shares outstanding |
35M | 0 |
| Nov 13, 2023 |
10-Q filing | 34.4M shares outstanding |
34M | 0 |
| Aug 11, 2023 |
10-Q filing | 34.4M shares outstanding |
34M | 0 |
| Aug 11, 2023 |
S-3 filing: The company may offer and sell up to $450,000,000 of any combination of common stock, preferred stock, or debt securities from time to time. Also offering common stock having an aggregate offering price of up to $150,000,000 through sales agents Cantor and Leerink Partners. |
34M | 0 |
| May 11, 2023 |
10-Q filing | 34.3M shares outstanding |
34M | 0 |
| Mar 14, 2023 |
10-K filing | 32.5M shares outstanding |
33M | 240K |
| Nov 10, 2022 |
10-Q filing | 29.9M shares outstanding |
30M | 2.9M |
| Aug 11, 2022 |
10-Q filing | 31.1M shares outstanding |
31M | 1.6M |
| Jun 24, 2022 |
S-3 filing: This S-3 filing registers the resale of up to 4,000,000 shares of common stock issuable upon the exercise of pre-funded warrants by the selling stockholder. |
30M | 3.1M |
| May 11, 2022 |
10-Q filing | 29.6M shares outstanding |
30M | 0 |
| Mar 10, 2022 |
10-K filing | 29.6M shares outstanding |
30M | 0 |
| Nov 10, 2021 |
10-Q filing | 29.5M shares outstanding |
30M | 0 |
| Aug 11, 2021 |
10-Q filing | 29.5M shares outstanding |
29M | 0 |
| May 11, 2021 |
10-Q filing | 25.0M shares outstanding |
25M | 3.8M |
| Mar 11, 2021 |
10-K filing | 24.9M shares outstanding |
25M | 3.9M |
| Nov 16, 2020 |
10-Q filing | 24.6M shares outstanding |
25M | 4.2M |
| Nov 04, 2020 |
S-3 filing: The filing is for a shelf registration statement covering common stock, preferred stock, and debt securities. Also covers offering of common stock by selling stockholders and ATM offering by the company. |
24M | 4.3M |
| Aug 13, 2020 |
10-Q filing | 24.5M shares outstanding |
24M | 0 |
| May 14, 2020 |
10-Q filing | 24.4M shares outstanding |
24M | 0 |
| Mar 30, 2020 |
10-K filing | 24.3M shares outstanding |
24M | 0 |